Spyre Therapeutics has reported statistically significant benefits from both doses of SPY072 compared to a placebo in treating rheumatoid arthritis. Although promising, results do not meet internal thresholds for advancing SPY072 as a monotherapy, indicating further investigation is needed.

Key Highlights

  • SPY072 Low Dose showed a significant reduction in the Disease Activity Score in 28 joints compared to placebo.
  • ACR20 response at Week 12 was 63% for the High Dose of SPY072 versus 43% for placebo.
  • Topline data for SPY072 in psoriatic arthritis and axial spondyloarthritis is expected in Q4 2026.

Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced on August 25, 2026, that its Phase 2 SKYWAY basket trial's rheumatoid arthritis (RA) sub-study delivered promising topline results for SPY072. Both the Low and High Dose of SPY072 demonstrated statistically significant improvements over placebo in various key endpoints, including the Disease Activity Score in 28 joints, confirmed by a reduction of -1.9 and -1.5 respectively for Low and High Dose. These findings could play a role in the ongoing exploration of SPY072 for additional treatment avenues.

SKYWAY-RA Results Overview

The primary endpoint focused on the change in Disease Activity Score at Week 12, while secondary objectives included the ACR20 response rate. Results revealed a notable difference in efficacy; the Low Dose of SPY072 achieved a significant change from baseline in DAS28-CRP, while the High Dose observed clinically relevant improvements on ACR20. This suggests a meaningful therapeutic potential, although the overall efficacy did not meet internal benchmarks to favor the compound's further development as a standalone treatment in RA.

Safety and Tolerability Profile

Safety evaluations indicated that SPY072 was generally well tolerated, aligning with the known safety profiles of TL1A class medications. Adverse event rates were 27% for the treatment group and 36% for the placebo group, with primary reactions classified as mild or moderate in severity. Serious treatment-emergent adverse events (TEAEs) were rare, with one occurring in each group, and neither was deemed drug-related.

Importantly, infections were prevalent across both groups, with rates at 14% for SPY072 and 15% for placebo. These findings highlight the drug's tolerability but underscore the need for ongoing monitoring as the compound progresses through clinical studies.

Implications for Future Development

The results from the SKYWAY-RA sub-study mark a key moment in Spyre Therapeutics' immunology portfolio, as they reaffirm the therapeutic mechanism of TL1A inhibition in autoimmune conditions. However, the company has chosen not to prioritize SPY072 as monotherapy for RA based on the magnitude of effect from the trial outcomes. This decision suggests a strategic pivot toward formulating combination therapies and exploring further applications in other autoimmune diseases.

Spyre projects topline results from additional studies in psoriatic arthritis and axial spondyloarthritis in the fourth quarter of 2026, as well as combinations with established treatments in hidradenitis suppurativa slated for late 2027 or early 2028.

What to Monitor Next

The clinical community will closely follow the expected topline results for the SKYWAY sub-studies in psoriatic arthritis and axial spondyloarthritis, anticipated in Q4 2026. These results could significantly influence the direction of Spyre's development pipeline and determine future investments in the TL1A antibody. The initiation of the SKYLIGHT trial in hidradenitis suppurativa, utilizing SPY072 in combination with IL-17A/F, is poised to further demonstrate the compound's versatility across diverse inflammatory conditions.